Clinical Update - Debio 025 in H... (l Besseghir CEOof Debiopharm S.A. This ...)

Clinical Update - Debio 025 in Hepatitis C

Date:4/28/2008

l Besseghir, CEO of Debiopharm S.A. "This unique mechanism of action is the first alternative treatment to classic HCV therapies."

Debio 025

Debio 025 is a synthetic first-in-class Cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in preclinical studies.

Previous results of a phase Ib study demonstrate that Debio 025 monotherapy for 15 days induced a strong anti-HCV effect (3.6 log10 reduction) in HIV-1/HCV co-infected patients. (Hepatology, Vol. 47, No 3, 2008, Flisiak et al. "The Cyclophilin Inhibitor Debio-025 Shows Potent Anti-Hepatitis C Effect in Patients Coinfected with Hepatitis C and Human Immunodeficiency Virus)."

About HCV

HCV is the most prevalent liver disease in the world and is considered by the World Health Organization as an epidemic. Because HCV can infect a patient for decades before being discovered, it is often called the "silent" epidemic. Studies suggest that over 200 million people worldwide are infected with HCV, an overall incidence of around 3.3% of the world's population. In the US alone, nearly 4 million people are or have been infected with HCV and of these, 2.7 million have an ongoing chronic infection, the majority being between 40 to 60 years old. A fourfold increase in the number of adults diagnosed with chronic HCV infection is projected from 1990 to 2015, since most persons with chronic HCV infection have yet to be diagnosed but are likely to come to medical attention in the next decade.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marke
'/>"/>

SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
2. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
3. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
4. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
5. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
6. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
9. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial

Post Your Comments:

(Date:12/16/2009)... -- Naurex Inc., a new clinical stage company ... disorders based on its novel GFPA NMDA receptor ... Phase I clinical trial of its lead compound ... in the study. GLYX-13, a glycine site ... NMDA receptor, is initially being developed as a ...

(Date:12/16/2009)... SAN DIEGO, Dec. 16 Optimer Pharmaceuticals, ... present at the 28th Annual J.P. Morgan Healthcare ... San Francisco on Wednesday, January 13, 2010. Michael ... will present at 2:30 p.m. Pacific Time (5:30 ... ,, A live audio webcast of this presentation ...

(Date:12/16/2009)... -- , - Studies ... and Published* in November 2009, in the Official ... Reveal new Benefits for,Peptan(TM) in Osteoporosis Prevention , ... concerns regarding long-term bone health,Rousselot has carried out, ... an oral intake of Peptan(TM) may have a ...

Breaking Medicine Technology:Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2 Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3 Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2 Published in "Bone" Journal, Scientific Researches Confirm Peptan(TM) Hydrolyzed Collagen Benefits on Bone Health 2 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 1 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 2 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 3 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 4 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 5 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 6 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 7 Mount Sinais Dr Benjamin tenOever to be honored by White House 9211 1 Mount Sinais Dr Benjamin tenOever to be honored by White House 9211 2 Mount Sinais Dr Benjamin tenOever to be honored by White House 9211 3 PTs say proper fit and use of walking aids can prevent fall related injuries in elderly 51371 1 PTs say proper fit and use of walking aids can prevent fall related injuries in elderly 51371 2

[0] Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression [0] Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference [0] Published in "Bone" Journal, Scientific Researches Confirm Peptan(TM) Hydrolyzed Collagen Benefits on Bone Health

... 2007 /PRNewswire-FirstCall/ --,CuraGen Corporation announced today that ... deacetylase (HDAC) inhibitor being,investigated for the treatment ... for the prevention of severe oral mucositis,will ... for Cancer,Research (AACR) 2007 Annual Meeting in ...

... April 11, 2007 /PRNewswire-FirstCall/ --,Advanced Magnetics today ... clinical trials of ferumoxytol as an,intravenous (IV) ... at approximately 6:00 pm EDT as posters ... in Orlando,Florida. These posters are available in ...

Other Medicine Technology:CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2 CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3 CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4 Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 2 Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 3 Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 4 Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 5 Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 6 Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 7 Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 8

CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic

(Date:12/16/2009)... Dec. 16 Dale Buchanan, owner of Supreme ... have a weight loss contest for his students in the ... students are not competing for their own prize or against ... for the Tri County Humane Society in Boca ... mine loses between January 4 and February 28, 2010 I ...

(Date:12/16/2009)... in the ,70s, study finds , , TUESDAY, Dec. 15 ... the United States than it was more than 30 ... Researchers compared National Health and Nutrition Examination Survey data ... 1972 and from 8,339 black and white participants from ... years old. , The prevalence of myopia increased from ...

(Date:12/16/2009)... interval lessens complication risks , , TUESDAY, Dec. 15 (HealthDay News) ... such a profound impact on your life that you just ... new study suggests that you might want to wait at ... than 11 months could be even better. , The ... than six months, the chances of the baby dying, being ...

(Date:12/16/2009)... money to help clothe children in need. , ... ... cleaner Dryclean USA Florida , along with Atlantic Awnings of Miami, ... help clothe children in need by collecting funds on behalf of ... cards, with delivery of their clean clothes, and pamphlets requesting donations ...

(Date:12/16/2009)... 2009) Unisense FertiliTech A/S has received a further 1.6 million Euro ... the EmbryoScope™ Embryo Monitoring System in order to meet the rapidly ... by LD Pensions and Unisense A/S that continue to own each ... ... (PRWEB) December 16, 2009 -- Unisense FertiliTech A/S has received a ...

Breaking Medicine News(10 mins):Health News:Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter 2 Health News:For Babies' Sake, Pregnancy Spacing Matters 2 Health News:For Babies' Sake, Pregnancy Spacing Matters 3 Health News:Pay a Dollar, Dress a Child: Helping Struggling Families with Small Donations 2 Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2

[0] Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter [0] Nearsightedness on the Increase [0] For Babies' Sake, Pregnancy Spacing Matters [0] Pay a Dollar, Dress a Child: Helping Struggling Families with Small Donations [0] Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device

... product revenue and reduced expenses continue to drive solid cash ... (Nasdaq: WCRX ) today announced its results for ... in the quarter ended December 31, 2008 totaled $242.5 million, ... for the year ended December 31, 2008 totaled $938.1 million, ...

... Novalar Pharmaceuticals, Inc., a dental specialty pharmaceutical ... company,s premier dental pharmaceutical product. OraVerse is the ... accelerates the return to normal sensation and function ... and unnecessary lingering soft tissue anesthesia following routine ...

... Feb. 27 /PRNewswire-Asia/ -- GE Healthcare, a,leading ... suite of,Centricity solutions targeted for hospitals and ... and advanced clinical capabilities,the suite provides the ... acquisition from Dynamic Imaging. , ...

... -- endorsed by,NaturalNews, Organic Consumers Association, Life Extension ... freedom groups --,calls for an end to FDA ... Its ten provisions also call for full income ... to the psychiatric drugging of,children, the end of ...

... Nursing Productivity in the Treatment of Renal Disease , ... ... 2009 -- iSirona®, an innovative provider of data automation solutions ... agreement with NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer ...

... Healthy Directions, LLC, is proud to announce the launch of searchjointpain.com, a ... conditions and solutions. , ... Potomac, MD (PRWEB) February 27, 2009 -- ... to announce the launch of searchjointpain.com , a new informational Web ...

Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 Video: Novalar Announces the Launch of OraVerse(TM) the First Dental Anesthesia Reversal Agent GE Healthcare Extends Leading Web-Based Imaging Solutions to Asia Health Freedom Groups Join in Launch of Grassroots Health Revolution Petition at HealthRevolutionPetition.org iSirona Signs Reference Selling Agreement with NxStage Healthy Living Network Announces Launch of New Joint Pain Web Site

... storage of blood plasma in full accordance ... to operating temperatures and performance means that ... freezer you will minimise bag cracking normally ... an additional benefit is reduced thawing time. ...

Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost times....

Plasma Blast Chest Freezer -50C - 8098/8091 maintains a -50C (-58F) temperature to rapidly freeze single donor, apheresed, and fresh frozen plasma. Rapid freezing also preserves Factor VIII. Full loa...

... complying with Australian Standard AS3864-1997 suitable to ... grey colorbond steel with a powder coated ... 40-litre capacity polished stainless steel compartment. Lid ... a heated top fascia. A removable chrome ...

Medicine Products:

Labcold™ Fresh Frozen Plasma Freezer i.Series Plasma Storage Freezer (-30C)Plasma Blast Chest Freezer -50C Chest-Style Plasma Freezer

Clinical Update - Debio 025 in H...(l Besseghir CEOof Debiopharm S.A. This ...),Health